Tuesday Case Conference

1. Tuesday Case Conference May 2009

2. Biopsy finding • LM • Glomeruli • are normal in size to mildly enlarged • Mild enlargement of the mesangial areas with occasional nodular appearance • Tubulointerstitial • Interstitial fibrosis and tubular atrophy, involving approximately 50% • Artery • Severe intimal fibrosis of arcuate artery • Sever cirucumferential hyalinosis of arterioles • IF • Negative for C4D, BKV, and CMV • EM • Podocyte effacement invovling ~40% of the surface area • Diagnosis: • Early Diabetic Nephropathy • IFTA related to CNI

3. Objectives • What are different causes of allograft failure? • What is Interstitial Fibrosis and Tubular Atrophy - Chronic Allograft Nephropathy? • A new biomarker for IFTA?

4. TransplantationThe preferred prescription for ESRD patients

5. Mortality on Dialysis

6. Graft survival increases with less time on dialysis Goldfarb-Rumyantzev A, et al. Nephrol Dial Transplant 2005;20:167–175

7. Risk of Death with Transplantation OJO, A. O. et al. J Am Soc Nephrol 2001;12:589-597

8. Renal Transplantation • Transplant is preferred prescription of choice for ESRD patients • Sooner the better • Dramatic improvement, since 1980s, 1-year allograft survival rates: 90-95% • Long-term outcomes have changed little • Death with a functioning graft • Chronic allograft nephropathy

9. Recurrent glomerulonephritis and other causes of graft failure 2002_NEJM_Briganti-Chadban_risk of renal allograft loss from recurrent glomerulonephritis

10. The most common cause of graft failure, after the first year

11. What is CAN – IFTA? • Incompletely understood clincopathological entity • chronic rejection, transplant nephropathy, chronic renal allograft dysfunction, trnasplant glomerulopathy, or chronic allograft nephropathy • Chronic Allograft Nephropathy • Banff 1991 • used interchangeably with ‘chronic rejection’ • Banff 1997 • term to be used when it is impossible to precisely define the etiology of chronic allograft damage • Banff 2005 • “interstitial fibrosis and tubular atrophy, without evidence of any specific etiology”

12. IF/TA (CAN) Interstitial fibrosis Fibrointimal proliferation Nankivell at ASN

13. Electron microscopic appearances in chronic allograft nephropathy

14. Some possible immune and nonimmune mechanisms of injury leading to chronic allograft nephropathy

15. IF/TA score Nankivell at ASN

16. Onset of IFTA • Very common • Progressive • Associated with • Proteinuria • Decreased GFR • hypertension 2003_NEJM_Nankivell-Chapman_antural history of chronic allograft nephropathy

17. Nankivell at ASN

18. Nankivell at ASN

19. Clinical Risk Factors for long-term allograft failure • IF/TA is a major cause of late allograft loss • Challenge is to dissect the identifiable causes and to develop cause-specific treatment • Existing risk factors/markers • Increased serum creatinine • Proteinuria • HTN

20. An innovative biomarker for IFTA?

21. Background • In kidney, interstitial fibrosis has been considered a common mechanism of disease progression • No effective treatment to revert established fibrosis and diagnosis is often late in the disease course • Fibroblasts are the pivotal effector cells in fibrogenesis • Studies looking to identify activated fibroblast found abnormal expression of mesenchymal markers (fibroblast) by tubular epithelial cells • Epithelial phenotypic changes (EPC)

22. Background • Epithelial-mesenchymal transformation (EMT) • where cell shifting between epithelial and mesenchymal phenotype is well recognized process that characterizes the embryonal plasticity • Key element in metastasis of tumors • Observed in the process of wound healing and fibrotic remodeling after inflammatory injury

23. Four key events during EMT 2006_ArthritisResTx_Zvaifler_Relevance of the stroma and epithelial mesenchymal transition_REV

24. Examined whether EPC of tubular cells predict the progression of fibrosis in the allograft Cytoplasmic translocation of β-catenin Expression of Vimentin intermediate filament typically expressed by mesenchymal cells 83 kidney tranplant with protocol graft biopsy at both 3 and 12 mo 2008_JASN_Hertig-Dubois_Early epithelial phenotypic changs predict graft fibrosis

25. Role of the Cadherins in Establishing Molecular Links between Adjacent Cells NEJM, 1996

26. Immunohistochemical stainingepithelial phenotypic change β-catenin Vimentin 2008_JASN_Hertig-Dubois_Early epithelial phenotypic changs predict graft fibrosis

27. IF/TA score and EPC status 2008_JASN_Hertig-Dubois_Early epithelial phenotypic changs predict graft fibrosis

28. Change in Serum Creatinine by EPC status 2008_JASN_Hertig-Dubois_Early epithelial phenotypic changs predict graft fibrosis

29. Conclusion • EPC (+) • an early and independent marker to predict the progression of IF/TA lesions between 3 and 12 mo after transplantation • Associated with poorer graft function from the time point of 18 mo and thereafter • Risk factors for renal graft fibrosis • 3-mo EPC score and 12-mo t scores were significantly higher in progressors as compared with nonprogressors

30. Treatment

31. Strategies to prevent and treat IFTA

32. Reference • Goldfarb-Rumyantzev A, et al. Nephrol Dial Transplant 2005;20:167–175 • OJO, A. O. et al. J Am Soc Nephrol 2001;12:589-597 • Briganti EM, Russ GR, McNeil J, et al: Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002;347:103–109 • Nankivell-Chapman, Natural history of chronic allograft nephropathy, NEJM, 2003 • Briganti-Chadban, Risk of renal allograft loss from recurrent glomerulonephritis, NEJM, 2003